SCHEMBL1471998

SCHEMBL1471998

CC(N)=NS(=O)(=O)c1cc(Cl)c(Oc2ccc([N+](=O)[O-])cc2)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 6/20 0.50
PRSS1 P07477 6/20 0.50
PRSS2 P07478 6/20 0.50
PRSS3 P35030 6/20 0.50
ALDH1A1 P00352 3/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 2/20 0.43
NOS1 P29475 2/20 0.42
THRA P10827 2/20 0.41
PDE7A Q13946 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP2C9 P11712 1/20 0.40
PTGS2 P35354 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
FAAH O00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471421 0.86 F2 (0.47) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL5798194 0.84 SMN1; SMN2 (0.62) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL1471814 0.84 ALDH1A1 (0.56) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL1471503 0.83 MAPT (0.53) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL1472388 0.80 CA2 (0.56) ALDH1A1MAPTSMN1; SMN2LMNATHRA
SCHEMBL1472081 0.80 MAPT (0.50) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL8411987 0.79 SMN1; SMN2 (0.48) ALDH1A1MAPTSMN1; SMN2LMNATHRA
SCHEMBL1472145 0.78 LMNA (0.43) ALDH1A1MAPTSMN1; SMN2LMNATHRA
SCHEMBL1472143 0.78 LMNA (0.43) ALDH1A1MAPTSMN1; SMN2LMNATHRA
SCHEMBL8408914 0.77 MEN1 (0.43) F2PRSS1PRSS2PRSS3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US claimed
EP-1651595-A2 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2006-05-03 EP claimed
WO-2005007621-A2 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-01-27 WO claimed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 US claimed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US disclosed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009871-A1 Ubiquitin ligase inhibitors NEDD4, STUB1, UBE3A F2 4699/4885PRSS1 2903/4885PRSS2 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.